subscribe
 

EKF to highlight new Glycated Albumin assay kit at AACC 2018

6th August 2018


Measurement of glycated albumin can confirm changes in blood glucose status 1 to 2 weeks after the commencement of treatment
EKF Diagnostics has announced that it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect hemoglobin point of care analyser at the AACC 2018 Clinical Lab Expo. Located in Chicago from July 31st to August 2nd, AACC is the world’s largest exposition for clinical laboratory products and services.
 
The Stanbio GA assay has FDA 510(k) clearance for sale in the USA. GA is a sensitive marker for intermediate glycemic control in diabetes and can fill the gap between long-term and short-term measurements of blood glucose status. This is particularly useful just after the start or during an alteration in diabetes treatment, where measurement of GA can confirm blood glucose changes over just 2 to 3 weeks. It is also useful for prognosis in hemodialysis patients and during pregnancy when HbA1c may provide an insufficient indication of glycemic levels.
 
The Stanbio Chemistry GA assay uses an enzymatic method with liquid reagents and requires no preparation. It can be used on compatible open channel clinical chemistry analysers and expresses results as a ratio of Glycated Albumin to Albumin in mmol/mol from a small amount of blood serum. GA accurately reflects the latest blood glucose status as it is found throughout the body and is a type of protein that can readily be glycated.
 
Also at AACC, EKF will be demonstrating the ease of use of its newly FDA 510(k) cleared and CLIA waived DiaSpect haemoglobin analyser. DiaSpect is a handheld and reagent-free system, ideally suited and cleared for use in point of care (POC) and Certificate of Waiver settings, including physician’s offices, clinics and other non-traditional laboratory locations.




Subscribe


Newsbrief

Twitter Icon © Setform Limited
subscribe